

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/528,353
				Filing Date	January 3, 2006
				First Named Inventor	Yasuda, Nobuyuki
				Art Unit	1615
				Examiner Name	RAE, Charlesworth E.
Sheet	1	of	2	Attorney Docket Number	082368-003300US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AO	US-6,011,155 A	01-04-2000	VILLHAUER, Edwin B.	
	AP	US-6,166,063 A	12-26-2000	VILLHAUER, Edwin B.	
	AQ	US-6,548,481 B1	04-15-2003	DEMUTH, Hans-Ulrich, et al.	
	AR	US-2002-0161001 A1	10-31-2002	KANSTRUP, Anders B., et al.	
	AS	US-2002-0198205 A1	12-26-2002	HIMMELSBACH, Frank, et al.	
	AT	US-2003-0105077 A1	06-05-2003	KANSTRUP, Anders B., et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	=5
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AU	WO	89/61431	A1	12-02-1996	Pro-Biolog Gesellschaft Für Arzneimittel/forschung mbH		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AV	BOUSHEY, Robin P., <i>et al.</i> ; "Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis;" <u>American Journal of Physiology</u> ; 1999; pp. E937-47; 277: (5 Pt. 1).			<input type="checkbox"/>
	AW	BOUSHEY, Robin P., <i>et al.</i> ; "Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor;" <u>Cancer Research</u> ; January 15, 2001; pp. 687-693; 61:2.			<input type="checkbox"/>
	AX	DRUCKER, Daniel J.; "Biological Actions and Therapeutic Potential of the Glucagon-like Peptides;" <u>Gastroenterology</u> ; 2002; pp. 531-544; 122:2.			<input type="checkbox"/>
	AY	DRUCKER, Daniel J.; "Get adaptation and the glucagon-like peptides;" <u>Gut</u> ; July 14, 2005; pp. 428-435; 50:3.			<input type="checkbox"/>
	AZ	MANNUCCI, Edoardo, <i>et al.</i> ; "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects;" <u>Diabetes Care</u> ; March 2001; pp. 489-494; 24:3.			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/528,353
				Filing Date	January 3, 2006
				First Named Inventor	Yasuda, Nobuyuki
				Art Unit	1615
				Examiner Name	RAE, Charlesworth E.
Sheet	2	of	2	Attorney Docket Number	082368-003300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BA	SIGALET, David L.; "ALX-0600 NPS Allelix Corp," <u>Current Opinion in Investigational Drugs</u> ; 2001; pp. 505-509; 2:4.	<input type="checkbox"/>
	BB	ZANDER, Mette, <i>et al.</i> ; "Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes," <u>Diabetes Care</u> ; April 2001; pp. 720-725; 24:4.	<input type="checkbox"/>

Examiner Signature	/Charlesworth Rae/	Date Considered	05/21/2008
-----------------------	--------------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.